The Effect of Increasing Factor X Levels on Emicizumab-Driven Coagulation Potential

Ecaterina Scarlatescu

DOI: https://doi.org/10.1055/a-2413-4453

2024-10-02

Thrombosis and Haemostasis

Abstract:Hemophilia A (HA) is a genetic bleeding disorder caused by a deficiency or defect in the factor VIII (FVIII) procoagulant protein. Regular use of FVIII products results in the development of anti-FVIII alloantibodies (inhibitors) in 20 to 30% of severe HA patients, increasing the risk of morbidity and mortality and complicating the management of these patients.[1] Until recently, the treatment options were limited to giving regular or as-needed bypassing agents, like recombinant activated factor VII (factor VIIa) or activated prothrombin complex concentrates, or inducing immune tolerance to eliminate FVIII inhibitors.[2] Currently, prophylaxis with emicizumab, a humanized bispecific antibody, is increasingly recognized as the standard of care for patients with HA, regardless of the presence of inhibitors. Emicizumab mimics FVIII cofactor activity by binding to activated factor IX and factor X (FX) to form a tenase complex that efficiently restores effective hemostasis.[3] In the recommended therapeutic concentrations, emicizumab significantly decreases bleeding events and corresponds to an FVIII activity level of 10 to 15 IU/dL assimilated to mild-phenotype hemophilia.[4] However, additional use of bypassing agents or FVIII is still necessary in patients receiving emicizumab in case of breakthrough bleeding or patients undergoing surgical procedures with high bleeding risk. In HA with inhibitors on emicizumab prophylaxis, the use of activated prothrombin complex concentrates was associated with thrombotic events, and the use of factor VIIa is recommended as the first-line treatment of bleeds.[5] Even if such adverse events were not reported with factor VIIa, the number of patients with HA with inhibitors treated for significant bleeding is limited until now; therefore, venous or arterial thrombotic events cannot be excluded. Moreover, recombinant factor VIIa should be administered frequently due to the short half-life of the product, making this therapy inconvenient; in certain situations, the bleeding does not stop after factor VIIa administration, and adding activated prothrombin complex concentrate is necessary, leading to an even higher risk of thrombotic complications. It is essential to understand how to increase the hemostatic activity of emicizumab and to discover alternative methods for managing breakthrough bleeding in HA patients with inhibitors who are using emicizumab. In the latest issue of Thrombosis and Haemostasis , Shimizu et al offer additional insight into the impact of elevating FX levels on the coagulation potential in HA patients with inhibitors who are being treated with emicizumab.[6] The authors used in vivo and in vitro experiments. They evaluated global coagulation potential using the adjusted maximum coagulation velocity from clot waveform analysis, peak thrombin, endogenous thrombin potential from thrombin generation assay (TGA), and clotting time, clot formation time and α parameter from rotational thromboelastometry.[6] In their in vitro experiments, the authors assessed the coagulation potential in FVIII-depleted plasmas and in plasma samples from patients with HA without inhibitors in which they added emicizumab (in a dose calculated to mimic the therapeutic concentration) and/or FX in increasing concentrations. When emicizumab alone was added to the FVIII-depleted plasma, the coagulation potential increased, and the supplemental addition of FX led to a more significant increase compared with baseline values. Adding FX only without emicizumab to FVIII-depleted plasma also led to an enhanced coagulation potential but of a lower magnitude than that obtained with emicizumab alone ([Fig. 1A]). Interestingly, if the adjusted maximum coagulation velocity from clot waveform analysis and the peak thrombin from TGA increased dose-dependently with the amount of FX added to FVIII-depleted plasma with or without emicizumab, the other parameter recorded from TGA, endogenous thrombin potential, did not show the same tendency to increase in parallel with FX concentrations. In a second experiment, the authors demonstrated similar effects on the coagulation potential when factor VIIa and FX (in adjusted doses to obtain the concentrations attained in clinical use) were added to plasma samples from patients with HA with inhibitors treated with emicizumab. In vivo, animal experiments used nonactivated rotational thromboelastometry to assess the hemostatic effects of increasing doses of FX in the presence of factor IX with or without emicizumab in HA mice. When only emicizumab or only coagulation factors were given, the coagulation parameters reflecting clotting initiation and propagation were not changed compared with untreated animals and improved only in animals treated simultaneously with emicizumab and coagulation factors ([Fig. 1B]). Clinically, the hemostatic changes induced by increasing doses of FX in the pr -Abstract Truncated-

peripheral vascular disease,hematology